Literature DB >> 11212262

Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.

L A Lambert1, G R Gibson, M Maloney, B Durell, R J Noelle, R J Barth.   

Abstract

We developed a technique for direct inguinal lymph node injection in mice to compare various routes of immunization with tumor lysate-pulsed dendritic cell (DC) vaccines. Syngeneic, bone marrow-derived, tumor lysate-pulsed DCs administered intranodally generated more potent protective antitumor immunity than s.c. or i.v. DC immunizations. Intranodal immunization with ovalbumin peptide-pulsed DCs induced significantly greater antigen-specific T-lymphocyte expansion in the spleen than either s.c. or i.v. immunization. Furthermore, a significantly more potent, antigen-specific TH1-type response to the ovalbumin peptide was induced by intranodal, compared with s.c. or i.v., immunization. Intranodal immunization, designed to enhance DC-T cell interaction in a lymphoid environment, optimizes induction of T lymphocyte-mediated protective antitumor immunity. These results support the use of intranodal immunization as a feasible and effective route of DC vaccine administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212262

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Authors:  Yefei Rong; Xia Qin; Dayong Jin; Wenhui Lou; Lili Wu; Dansong Wang; Wenchuan Wu; Xiaolin Ni; Zhengfa Mao; Tiantao Kuang; Ying Qin Zang; Xinyu Qin
Journal:  Clin Exp Med       Date:  2011-09-20       Impact factor: 3.984

2.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

3.  Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.

Authors:  Camilo E Fadul; Jan L Fisher; Thomas H Hampton; Enrico C Lallana; Zhongze Li; Jiang Gui; Zbigniew M Szczepiorkowski; Tor D Tosteson; C Harker Rhodes; Heather A Wishart; Lionel D Lewis; Marc S Ernstoff
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

4.  Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Authors:  Huafeng Wei; Pu Liu; Elizabeth Swisher; Yuen Yee Yip; Jee Hang Tse; Kathy Agnew; Karl Erik Hellström; Ingegerd Hellström
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

Review 5.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 6.  Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients.

Authors:  Xue-jun Dai; Wei-jian Jiang; Wei-min Wang; Shu-jin Zhao
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

7.  Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity.

Authors:  Wei Guo; Yi Guo; Shun Tang; Huayi Qu; Hui Zhao
Journal:  Clin Orthop Relat Res       Date:  2008-06-19       Impact factor: 4.176

8.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

Review 9.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

10.  Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Authors:  Thomas Schwaab; Adrian Schwarzer; Benita Wolf; Todd S Crocenzi; John D Seigne; Nancy A Crosby; Bernard F Cole; Jan L Fisher; Jill C Uhlenhake; Diane Mellinger; Cathy Foster; Zbigniew M Szczepiorkowski; Susan M Webber; Alan R Schned; Robert D Harris; Richard J Barth; John A Heaney; Randolph J Noelle; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.